Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy
Lung Cancer Mar 15, 2018
Bradbury PA, et al. - This trial demonstrated no improvement in the progression free survival (PFS) of non-small cell lung cancer (NSCLC) patients following treatment with pelareorep added to second-line chemotherapy. In addition, the tolerability of three-day pelareorep schedule was shown.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
